Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Phase 2
Not yet recruiting
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 778
- Registration Number
- NCT06841679
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases
Phase 2
Recruiting
- Conditions
- HER2-negative Breast Cancer Patients with Brain Metastases
- Interventions
- Drug: Utidelone in combination with capecitabine
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Biostar Pharma, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06764940
- Locations
- 🇺🇸
FOMAT Medical Research (Network), Oxnard, California, United States
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Gastric Cancer Adenocarcinoma MetastaticOvarian CancerBile Duct Cancer
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06730581
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
Phase 2
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer Patients with Brain Metastases
- Interventions
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT06683703
Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05700084
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer
Phase 3
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 552
- Registration Number
- NCT05673629
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 612
- Registration Number
- NCT05673590
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Advanced and Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05052437
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04911907
- Locations
- 🇨🇳
Luhe Hospital, Capital Medical University, Beijing, China
🇨🇳Shanghai East Hospital of Tongji University, Shanghai, China
🇨🇳Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03906565
- Locations
- 🇨🇳
Tianjin People's Hospital, Tianjin, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
© Copyright 2025. All Rights Reserved by MedPath